EPIsoDE Trial: Long-Term Psilocybin Efficacy for Depression at 6- and 12-Months

126 participants from a phase 2b trial provided data for a naturalistic follow-up study on psilocybin for treatment-resistant depression. The dataset, published by figshare admin karger in 2026, includes primary endpoint changes on the Hamilton Rating Scale for Depression (HAMD17) at six- and twelve-month intervals. Results show significant and stable antidepressant effects up to twelve months.

Use Cases

• Modeling long-term treatment response trajectories based on HAMD17 score changes over time.
• Analyzing the association between antidepressant pharmacotherapy re-initiation and depression scores during follow-up.
• Comparing outcomes across different psilocybin dosing regimens mentioned in the trial design.
• Investigating the stability of clinical effects in a naturalistic follow-up setting after a controlled trial.

Strengths

• Includes data from 126 participants, described as the largest and most complete follow-up of any clinical psychedelic trial.
• Provides longitudinal data with follow-up assessments at two time points (6 and 12 months).
• Results are based on a generalized additive mixed regression model with reported confidence intervals and p-values.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset files are in PDF and DOCX formats (3.9 MB total), which may require extraction for structured analysis.

Provenance

Source

figshare admin karger

Collection Method

Naturalistic follow-up of a randomized, active placebo-controlled phase 2b clinical trial.

Time Range

Follow-up assessments at 6 and 12 months post-baseline.

Freshness

Last updated 2026-05-27 05:55:14; freshness should be verified.